メタボリックリワイヤリングは,グルココルチコイドの抗炎症効果を促進します

Jean-Philippe Auger^1,2, Max Zimmermann^1,2, Maria Faas^1,2

¹Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Nature

|April 10, 2024

まとめ

抗炎症化合物イタコナートを活性化することで,マクロファージの代謝を変化させ,炎症を軽減します. このミトコンドリア経路の再配線は炎症反応とサイトカインの生成を阻害します

科学分野:

免疫学
代謝経路
薬理学について

背景:

グルココルチコイドは,免疫媒介の炎症性疾患の主要な治療法である.
正確な抗炎症メカニズムは完全に理解されていません.

研究の目的:

グルココルチコイドの抗炎症効果の背後にある分子メカニズムを解明する.
グルココルチコイド作用におけるミトコンドリア代謝の役割を調査する.

主な方法:

グルココルチコイド受容体とピルベート脱水素酶複合体の相互作用を研究した.
マクロファージにおけるトリカルボキシル酸 (TCA) サイクルフルスとイタコナート生成を分析した.
遺伝的欠乏症モデル (アコニテットデカルボキラーゼ1) とTCAサイクルブロッカーを使用した.

主要な成果:

グルココルチコイドはマクロファージのミトコンドリア代謝を再プログラムし,イタコナート生成を増加させます.
この代謝の変化はTCAサイクルを加速し,持続的なイタコナート合成につながります.
イタコナート生成は炎症誘発性サイトカイン生成を抑制する.
TCAサイクルやイタコナート合成を阻害すると,前臨床モデルにおけるグルココルチコイドの抗炎症効果は無効になる.

結論:

抗炎症作用はミトコンドリアの代謝を再プログラムしてイタコネート生成を促進します.
この経路をターゲットにすることで新しい抗炎症薬の開発の可能性が生まれます

さらに関連する動画

07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

38.7K

06:26

Analyzing Ex Vivo Metabolic Flux in Splenic and Cardiac Macrophages and Bone Marrow Monocytes

Published on: March 28, 2025

208

関連する概念動画

01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

116

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

116

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

161

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

161

01:28

Inflammatory Response

2.0K

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

2.0K

01:29

Inflammatory Bowel Disease IV: Pharmacological Management

127

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

127

01:24

Glucagon-like Receptor Agonists

319

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

319

01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

136

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

136

関連する実験動画